The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | SCG101: a novel T-cell therapy in advanced hepatitis B-related HCC
Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, discusses an ongoing Phase I trial (NCT05417932) evaluating the safety and efficacy of autologous SCG101 T cell therapy in patients with advanced hepatitis B-related hepatocellular carcinoma (HCC). The primary endpoints of the trial include safety, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D). Secondary endpoints include objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and changes in serum HBsAg levels. The trial is actively enrolling, with the Phase II portion expected to commence by the second half of 2023. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
